Zi Ming Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zi Ming Li has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Zhixian Gao
Tianjin Key Laboratory of Risk Assessment and Control Technology for Environment and Food Safety, Military Medical Sciences Academy, Academy of Military Sciences, Tianjin, 300050, China
2 shared publications - Zhiyong Hu
School of Public Health, Binzhou Medical University, Yantai, China
2 shared publications
Latest Publications
- Open Access
- 11 March 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (3) , 278
Advances in the Study of Age-Related Macular Degeneration Based on Cell or Cell-Biomaterial Scaffolds
Age-related macular degeneration (AMD), a progressive neurodegenerative disorder affecting the central retina, is pathologically defined by the irreversible degeneration of photoreceptors and retinal pigment epithelium (RPE), coupled with extracellular drusen deposition and choroidal neovascularization (CNV), and AMD constitutes the predominant etiological factor for irreversible vision impairment in adults aged ≥60 years. Cell-based or cell-biomaterial scaffold-based approaches have been popular in recent years as a major research direction for AMD; monotherapy with cell-based approaches typically involves subretinal injection of progenitor-derived or stem cell-derived RPE cells to restore retinal homeostasis. Meanwhile, cell-biomaterial scaffolds delivered to the lesion site by vector transplantation have been widely developed, and the implanted cell-biomaterial scaffolds can promote the reintegration of cells at the lesion site and solve the problems of translocation and discrete cellular structure produced by cell injection. While these therapeutic strategies demonstrate preliminary efficacy, rigorous preclinical validation and clinical trials remain imperative to validate their long-term safety, functional durability, and therapeutic consistency. This review synthesizes current advancements and translational challenges in cell-based and cell-biomaterial scaffold approaches for AMD, aiming to inform future development of targeted interventions for AMD pathogenesis and management.
- 11 March 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (3) , 278
Open AccessAdvances in the Study of Age-Related Macular Degeneration Based on Cell or Cell-Biomaterial Scaffolds
Age-related macular degeneration (AMD), a progressive neurodegenerative disorder affecting the central retina, is pathologically defined by the irreversible degeneration of photoreceptors and retinal pigment epithelium (RPE), coupled with extracellular drusen deposition and choroidal neovascularization (CNV), and AMD constitutes the predominant etiological factor for irreversible vision impairment in adults aged ≥60 years. Cell-based or cell-biomaterial scaffold-based approaches have been popular in recent years as a major research direction for AMD; monotherapy with cell-based approaches typically involves subretinal injection of progenitor-derived or stem cell-derived RPE cells to restore retinal homeostasis. Meanwhile, cell-biomaterial scaffolds delivered to the lesion site by vector transplantation have been widely developed, and the implanted cell-biomaterial scaffolds can promote the reintegration of cells at the lesion site and solve the problems of translocation and discrete cellular structure produced by cell injection. While these therapeutic strategies demonstrate preliminary efficacy, rigorous preclinical validation and clinical trials remain imperative to validate their long-term safety, functional durability, and therapeutic consistency. This review synthesizes current advancements and translational challenges in cell-based and cell-biomaterial scaffold approaches for AMD, aiming to inform future development of targeted interventions for AMD pathogenesis and management.
- Open Access
- 5 February 2025
- Published by MDPI AG in Preprints.org
Advances in Cell-Based or Cell-Biomaterial Scaffolds for the Treatment of Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a degenerative retina disease characterized by irreversible damage to macular cells and has become one of the leading causes of blindness in the elderly worldwide. Therapies based on cells or cell-biomaterial scaffolds are popular AMD treatments in recent years, where cell therapy is the use of cell types such as progenitor/stem cells, which are delivered into the subretinal space by injection or vector transplantation to treat AMD. Meanwhile, cell-biomaterial scaffolds delivered to the lesion site by vector transplantation have been widely developed, and the implanted cell-biomaterial scaffolds implanted cell-biomaterial scaffolds can promote the reintegration of cells at the lesion site and solve the problems of translocation and discrete cellular structure produced by cell injection. Although these methods have achieved some results, a large number of preclinical studies and clinical trials are still needed to verify their stability and reliability. Therefore, this article provides a review of the latest findings and real-life challenges of cell-based and cell-biomaterial scaffolds for the treatment of AMD to offer new ideas for subsequent disease prevention and treatment of AMD.
- 5 February 2025
- Published by MDPI AG in Preprints.org
Open AccessAdvances in Cell-Based or Cell-Biomaterial Scaffolds for the Treatment of Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a degenerative retina disease characterized by irreversible damage to macular cells and has become one of the leading causes of blindness in the elderly worldwide. Therapies based on cells or cell-biomaterial scaffolds are popular AMD treatments in recent years, where cell therapy is the use of cell types such as progenitor/stem cells, which are delivered into the subretinal space by injection or vector transplantation to treat AMD. Meanwhile, cell-biomaterial scaffolds delivered to the lesion site by vector transplantation have been widely developed, and the implanted cell-biomaterial scaffolds implanted cell-biomaterial scaffolds can promote the reintegration of cells at the lesion site and solve the problems of translocation and discrete cellular structure produced by cell injection. Although these methods have achieved some results, a large number of preclinical studies and clinical trials are still needed to verify their stability and reliability. Therefore, this article provides a review of the latest findings and real-life challenges of cell-based and cell-biomaterial scaffolds for the treatment of AMD to offer new ideas for subsequent disease prevention and treatment of AMD.